CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CURIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.38−0.03 (-6.26%)
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
CURIS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 22 | Q3 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | – | – | – | – | – | – | – | – | – | – | $2.90M | $2.84M | – | – |
| Contra revenue, net | – | – | – | – | – | – | – | – | – | – | – | -$18.00K | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Curis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.